Aspire Biopharma Holdings (ASBP) EBITDA (2024 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly EBITDA of -$1.6 million for Q1 2026, up 89.42% year-over-year from -$869066.3 in Q1 2025, and up 10.99% quarter-over-quarter from -$1.8 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) EBITDA (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported EBITDA for 3 consecutive years, with -$1.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 89.42% year-over-year to -$1.6 million; the TTM figure through Mar 2026 stood at -$20.2 million (changed N/A YoY), while the FY2025 annual figure was -$19.4 million, down 1498.13% from the prior year.
- EBITDA improved to -$1.6 million in Q1 2026 per ASBP's latest filing, from -$1.8 million in the prior quarter.
- Across five years, EBITDA topped out at -$215256.0 in Q3 2024 and bottomed at -$15.6 million in Q1 2025.
- Historically, EBITDA has averaged -$3.5 million across 3 years, with a median of -$1.4 million in 2025.
- Annual changes were most pronounced in 2025 — EBITDA slumped 432.16% — and 2026, when it surged 89.42%.
- Aspire Biopharma Holdings' EBITDA stood at -$667722.0 in 2024, then slumped by 176.98% to -$1.8 million in 2025, then climbed by 10.99% to -$1.6 million in 2026.
- Business Quant data shows ASBP's EBITDA at -$1.6 million in Q1 2026, -$1.8 million in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 133.12 Mn |
| 10 | Aspire Biopharma Holdings | 8.29 Mn | -3.87 Mn | -30,086.00 | -2.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.68 Mn |
| Mar 31, 2026 | -1.65 Mn |
| Dec 31, 2025 | -1.85 Mn |
| Sep 30, 2025 | -1.15 Mn |
| Mar 31, 2025 | -15.56 Mn |
| Dec 31, 2024 | -667,722.00 |
| Sep 30, 2024 | -215,256.00 |